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Background: Premature discontinuation of treatment impacts outcomes of clinical practice. 
The traditional perception has been patient discontinuation is mainly driven by unwanted side 
effects. Systematic analysis of data from clinical trials across several disease states was performed 
to identify predictors of premature discontinuation during clinical interventions.
Methods: A post hoc analysis was conducted on 22 randomized, double-blind, placebo-controlled 
clinical trials for treatment of ﬁ  bromyalgia, diabetic peripheral neuropathic pain, major depres-
sive disorder, and generalized anxiety disorder. Analyses were conducted on pooled data within 
each disease state.
Results: Lack of early therapeutic response was a signiﬁ  cant predictor of patient discontinu-
ation in each disease state. Visit-wise changes in therapeutic response and severity of adverse 
events were also signiﬁ  cant risk factors, with change in therapeutic response having a higher 
signiﬁ  cance level in three disease states. Patients who discontinued due to adverse events had 
similar therapeutic responses as patients completing treatment.
Conclusion: Contrary to the conventional belief that premature treatment discontinuation 
is primarily related to adverse events, our ﬁ  ndings suggest lack of therapeutic response also 
plays a signiﬁ  cant role in patient attrition. This research highlights the importance of system-
atic monitoring of therapeutic response in clinical practice as a measure to prevent patients’ 
discontinuation from pharmacological treatments.
Keywords: attrition, depression, generalized anxiety disorder, ﬁ  bromyalgia, therapeutic 
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Background
Treatment discontinuation from clinical interventions is a widespread phenomenon 
that occurs across disease states. It has been shown that patients who discontinue 
prematurely are likely to experience relapse of symptoms and other undesirable 
effects.1,2 The issue of patient attrition also impacts the analysis of clinical studies. 
For example, a reduction in sample size threatens the internal validity of a clinical 
study and limits generalizability of results.3 Identiﬁ  cation of factors that inﬂ  uence 
treatment discontinuation could lead to optimization of interventions and improved 
patient outcomes.
It is a common practice in clinical trials to record the reasons for discontinuation 
along with the percentage of patients who discontinue from the study. A review 
of published clinical trial results indicates that attrition rates among diabetic 
neuropathy clinical trials have ranged from 20% to 40%,4–8 18% to 26% among 
ﬁ  bromyalgia clinical trials,9–13 23% to 38% among generalized anxiety disorder 
clinical trials,14–17 and 20% to 40%,among major depressive disorder clinical trials.18 
The two categories of treatment-related reasons for discontinuation are adverse 
events and lack of therapeutic response. The traditional perception has been that 
patient discontinuation is driven mainly by adverse events. Statistical analysis Patient Preference and Adherence 2009:3 32
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techniques can be utilized to further assess the risk factors 
of discontinuation.3,18,23 Previously conducted research has 
found that poor therapeutic response and poor medication 
tolerability were signiﬁ  cant predictors of patient discon-
tinuation in schizophrenia clinical trials.19 In the Sequenced 
Treatment Alternatives to Relieve Depression (STAR*D) 
study, patient attrition was associated with younger age, 
less education, and African American race.18 Since ran-
domized, controlled clinical trials provide information 
on therapeutic response and reasons for discontinuation; 
we conducted exploratory analyses of 22 clinical trials 
to systematically investigate the predictors of treatment 
discontinuation and, particularly, the relative impact of 
therapeutic response versus the impact of adverse events. 
This research was done in multiple disease states: major 
depressive disorder (MDD), diabetic peripheral neuro-
pathic pain (DPNP), generalized anxiety disorder (GAD), 
and ﬁ  bromyalgia (FM).
Methods
Patient population
This was a post hoc, pooled analysis of clinical trials 
within the Eli Lilly and Company duloxetine database. 
The selection criteria for the clinical trials included in 
this research were 1) randomized, double-blind, placebo-
controlled, 2) disease states of major depressive disorder 
(MDD), diabetic peripheral neuropathic pain (DPNP), 
ﬁ  bromyalgia (FM), or generalized anxiety disorder (GAD), 
and 3) same primary efﬁ  cacy measure for all studies within 
a disease state. Twenty-two studies met these criteria, with 
3 studies of DPNP, 4 studies of FM, 4 studies of GAD, 
and 11 studies of MDD. All treatment groups were pooled 
together within each disease state for the purpose of this 
research.
Study designs
Analyses were conducted using the acute therapy phase 
of each clinical trial, during which treatment response and 
safety of treatment are evaluated for each patient. The DPNP 
studies included 1139 patients treated with duloxetine or 
placebo. The FM studies included 1411 patients treated 
with duloxetine or placebo. The GAD studies included 
1908 patients treated with duloxetine, venlafaxine, or 
placebo. The MDD studies included 3270 patients treated 
with duloxetine, clomipramine, ﬂ  uoxetine, paroxetine, 
escitalopram, or placebo. For each disease state, treatment 
duration for the studies varied: DPNP (12–13 weeks), 
FM (3–6 months), GAD (9–10 weeks), MDD (4–12 weeks). 
The FM studies also had extension phases of either 3 or 
6 months.
Assessments
The primary objective of this analysis was to assess the 
pattern and reasons for discontinuation by pooling the 
data within the disease states of MDD, DPNP, GAD, and 
FM. Investigators in all studies were required to record the 
reason and date of discontinuation when patients left the 
trial before completing it. The reasons for discontinuation 
were as follows:
1) Lack of efﬁ  cacy (LOE): The patient perception was 
that symptom improvement was not adequate. 2) Adverse 
event (AE): The patient experiences an unwanted side effect 
(with the event speciﬁ  ed). 3) Subject decision: The patient 
decides to discontinue treatment for personal reasons, 
such as transportation, inconvenience and personal reloca-
tion. 4) Lost to follow-up: The patient did not come to a 
scheduled visit and could not be reached by phone or mail. 
5) Physician decision: The physician decided that the patient 
should be discontinued due to reasons other than LOE or 
AE. 6) Protocol violation or violation of entry criteria: The 
requirements and procedures speciﬁ  ed by the protocol were 
not followed or the patient was inappropriately enrolled into 
the clinical trial based on speciﬁ  c entry criteria. 7) Sponsor 
decision: The sponsor (Eli Lilly and Company) decided that 
a patient should be discontinued following consultation with 
the investigator treating the patient.
The primary efﬁ  cacy measures recorded for each patient 
in these clinical trials were Likert scales, in which lower 
scores indicated lower presence of symptoms and higher 
scores indicated higher presence of symptoms. In the DPNP, 
FM, GAD, and MDD clinical trials, the primary efﬁ  cacy 
measures were the weekly mean of the 24-hour average pain 
ratings, the 24-hour average pain item from the Brief Pain 
Inventory (BPI), the Hamilton Anxiety Rating Scale Total 
Score (HAMA), and the total score of the 17-item Hamilton 
Depression Rating Scale (HAMD-17), respectively. The 
Likert scales used for these primary efﬁ  cacy measures ranged 
from 0 (no pain) to 10 (the most severe pain) for the DPNP 
and FM clinical trials, 0 (not present) to 56 (very severe) for 
the GAD clinical trials, and 0 (not depressed) to 68 (severely 
depressed) for the MDD clinical trials.
At each study visit, severity of adverse events was rated 
based on patients’ spontaneous reports using the scale 
where 1 indicates a mild event (noted change in patient’s 
condition that does not affect their usual activity), 2 indicates 
a moderately severe event (a mild disruption in patient’s usual Patient Preference and Adherence 2009:3 33
Predictors of premature treatment discontinuation
activity), 3 indicates a severe event (a major disruption in 
patient’s usual activity), and 0 indicates no adverse events 
experienced during the visit. The maximum event severity 
rating of all adverse events for each patient at each visit was 
used in all statistical analyses.
Statistical methods
All statistical analyses were conducted separately for each 
of the four disease states, with treatment groups combined 
within each disease state. Summary statistics describing 
baseline demographics and illness severity are presented as 
means and standard deviations for continuous variables and 
percentages for discrete variables. A two-sided alpha level 
of 0.05 was used for tests of signiﬁ  cance.
To assess the predictive value of early therapeutic 
response, lack of early therapeutic response, and adverse 
reaction, a stepwise logistic regression analysis was 
implemented to determine factors associated with patient 
discontinuation, using baseline demographic factors as well 
as percent change in therapeutic response from baseline visit 
(PCTHR) and maximum event severity rating (MXSEV) 
at the ﬁ  rst post-baseline visit. Entry and exit of covariates 
was determined using an alpha level of 0.05. Standardized 
versions of PCTHR and MXSEV were formed to produce a 
common scale and facilitate clear interpretations; standard-
ized therapeutic response (STR) and standardized adverse 
reaction (SAR).
In order to evaluate the continuous effect of therapeutic 
response and adverse reactions in treatment discontinuation 
throughout the therapy phase, a stepwise Cox regression 
model using demographic factors and visit-wise PCTHR and 
MXSEV as time-varying covariates was used. As in the logis-
tic regression analysis, entry and exit of covariates was deter-
mined using an alpha level of 0.05 and standardized versions 
of PCTHR and MXSEV (STR and SAR respectively) were 
formed for clearer interpretations.
For statistical models such as the logistic regression and 
Cox regression models, the value of the maximum likeli-
hood function measures the agreement between the proposed 
model and the observed data using the particular set of predic-
tors included in the model. Let L(full) denote the maximized 
likelihood value for the full predictive model, and L(reduced) 
denote the maximized likelihood for the reduced model. The 
full model contains the predictors STR, SAR, and any addi-
tional signiﬁ  cant predictors, while the reduced model con-
tains the same predictors as the full model, but without either 
STR or SAR. To determine whether STR or SAR contributes 
more to the ﬁ  nal model predicting patient discontinuation, 
two likelihood ratio tests were conducted. These two tests 
involved computing the difference of (−2*log(L(reduced))) 
and (−2*log(L(full))) which is distributed as a chi-square 
distribution with one degree of freedom. A large difference 
indicates that the additional predictor of either STR or SAR 
in the ﬁ  nal model compared to the model that excluded one of 
those predictors improves the adequacy of the ﬁ  nal model.21 
The test that produces the largest difference determined 
which predictor (STR or SAR) contributed more to the ﬁ  nal 
predictive model.
Analysis of variance (ANOVA) was used to compare the 
differences in therapeutic response between patients who 
discontinue before the end of the therapy phase and patients 
who completed the acute therapy. A similar analysis was 
also conducted where patients who discontinued due to vari-
ous reasons as well as completers were compared. Results 
of the ANOVA analysis were presented using least-square 
means plots of treatment efﬁ  cacy for the different groups of 
patients at time points common in all studies within each 
disease state.
Results
Table 1 summarizes the sample of patients at baseline across 
the 4 disease states with treatment groups combined. A major-
ity of patients were female (66%) and Caucasian (83%). The 
patient mean age was 46.05 ± 13.80. The mean baseline BPI 
average pain score for FM patients was 6.44 ± 1.57. The 
baseline weekly mean of the 24-hour average pain rating 
for DPNP patients was 5.83 ± 1.47. The mean baseline 
HAMA total score for GAD patients was 25.55 ± 7.22. The 
mean baseline HAMD-17 total score for MDD patients was 
19.68 ± 5.00.
Reasons for discontinuation
The reasons for discontinuation are summarized in Table 2. 
About one-third of the patients discontinued from these 
22 studies. The studies for FM had the highest overall 
discontinuation rate (42%) and the studies for DPNP had the 
lowest overall discontinuation rate (22%). Discontinuations 
due to lack of efﬁ  cacy were highest in MDD studies (27%) 
and lowest in DPNP studies (7.5%). With the exception 
of MDD studies, each other disease state had a higher rate 
of discontinuations due to adverse reactions than lack of 
therapeutic response.
Baseline predictors of discontinuation
Certain demographic factors were associated with discontinu-
ation. African American patients were 1.6 times more likely Patient Preference and Adherence 2009:3 34
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to discontinue than Caucasian patients in MDD clinical trials. 
Age was also associated with patient discontinuation in MDD 
and GAD clinical trials. For each additional 10 years of age 
respectively the odds of discontinuation decreased by a factor 
of 0.9 and 0.98. Patients treated in European countries were 
0.44 times more likely to discontinue than patients treated 
in the United States in DPNP clinical trials.
Early predictors of discontinuation
In the FM, MDD, and GAD disease states, standardized 
adverse reaction and standardized therapeutic response at 
ﬁ  rst post-baseline visit were signiﬁ  cant predictors of study 
completion. In the DPNP disease state, SAR was a signiﬁ  -
cant predictor of study completion but not STR (Table 4). 
For every increase of one standard deviation in STR (SAR) 
which indicates worse outcomes, the odds of discontinuing 
from the study were increased by 20% (14%), 19% (23%), 
22% (25%) for patients in the MDD, FM, and GAD disease 
states, respectively. For patients in the DPNP disease state, 
the odds of discontinuing from the study were increased by 
58% for every increase of one standard deviation in SAR, 
but STR was not identiﬁ  ed as a signiﬁ  cant predictor in the 
stepwise logistic regression procedure. In the FM and GAD 
disease states, SAR was identiﬁ  ed ahead of STR in the 
stepwise logistic regression procedures, while the opposite 
was true for MDD.
Table 5 contains the results of the likelihood ratio tests 
comparing the full models predicting the probability of 
discontinuation in each disease state with models missing 
either standardized therapeutic response or standardized 
adverse reaction. In the FM, MDD, and GAD disease states, 
the inclusion of STR to the full logistic regression model 
produced a larger difference than the inclusion of SAR, 
indicating that STR contributed more to the ﬁ  nal model. 
Even though the stepwise logistic regression procedure 
did not identify STR as a signiﬁ  cant predictor of study 
completion in the DPNP disease state, the likelihood ratio 
test procedure demonstrated that the inclusion of STR 
contributed more to the ﬁ  nal predictive model than the 
inclusion of SAR.
Continuous predictors of discontinuation
In all four disease states, symptom improvement from 
the baseline visit to each visit after baseline as measured 
Table 1 Baseline patient characteristics
Variable MDD (n = 3270) DPNP (n = 1139) FM (n = 1411) GAD (n = 1908) Total (N = 7728)
Age, mean (SD) 41.59 (12.38) 59.90 (10.62) 50.24 (10.98) 42.33 (13.33) 46.05 (13.80)
Sex, n (%)
  Female 2099 (64%) 492 (43%) 1338 (95%) 1187 (62%) 5116 (66%)
  Male 1171 (36%) 647 (57%) 73 (5%) 721 (38%) 2612 (34%)
Race/ethnicity, n (%)
  Caucasian 2720 (83%) 961 (84%) 1234 (88%) 1494 (78%) 6409 (83%)
  African 236 (7%) 48 (4%) 33 (2%) 127 (7%) 444 (6%)
 American
Baseline Illness Severity 
(mean (SD))
19.68 (5.00) 5.83 (1.47) 6.44 (1.57) 25.55 (7.22) N/A
Notes: Illness severity measured by BPI (Brief Pain Inventory) for FM studies, 24-hour average pain rating for DPNP studies, HAMA (Hamilton Anxiety Rating Scale) for GAD 
studies, and HAMD-17 (Hamilton Depression Rating Scale) for MDD studies.
Abbreviations: MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder.
Table 2 Reasons for discontinuation by disease state
Reason for 
discontinuation
MDD (n = 3270) DPNP (n = 1139) FM (n = 1411) GAD (n = 1908) Total (n = 7728)
Overall discontinuation 1124 (34.4%) 252 (22.1%) 589 (41.7%) 632 (33.1%) 2597 (34.0%)
Lack of efﬁ  cacy 304 (27.1%) 19 (7.5%) 133 (22.6%) 78 (12.3%) 534 (20.6%)
Adverse events 274(24.4%) 118 (46.8%) 234 (39.7%) 199 (31.5%) 825 (31.8%)
Other reasonsa 546 (48.6%) 115 (45.6%) 222 (37.7%) 355 (56.2%) 1238 (47.7%)
aOther reasons for discontinuation included lost to follow-up, physician decision, protocol violation, entry criteria not met, subject decision, sponsor decision.
Abbreviations: MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder.Patient Preference and Adherence 2009:3 35
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by STR and SAR in each post-baseline visit were signiﬁ  -
cantly predictive of the risk of discontinuation (Table 6). 
The increased risk in discontinuation for patients in the 
FM, MDD, and DPNP disease states who experienced an 
increase (worsening) of one standard deviation in STR 
was approximately 45% over patients with no increase 
(worsening) in STR. For each of these three disease states, 
STR was identiﬁ  ed ahead of SAR during the stepwise regres-
sion procedure. Patients in DPNP studies experienced a 25% 
increased risk in discontinuation for every increase of one 
standard deviation in STR over patients with no increase in 
STR. In the DPNP disease state, SAR was identiﬁ  ed ahead of 
STR during the stepwise regression procedure. The increased 
risk of discontinuation for patients who experienced an 
increase of one standard deviation in SAR ranged from 34% 
to 47% in FM, MDD, and GAD studies over patients with 
no increase in SAR, and 87% for DPNP study patients over 
patients with no increase in SAR.
Table 7 contains the results of the likelihood ratio tests 
comparing the full models predicting risk of discontinuation 
in each disease state with models missing either standardized 
therapeutic response or standardized adverse reaction. 
In the FM, MDD, and GAD disease states, the inclusion 
STR to the ﬁ  nal Cox regression model produced a larger 
difference statistic than the inclusion of SAR, indicating 
that STR contributed more to the ﬁ  nal model. In the DPNP 
Table 3 Average discontinuation percentages by disease state and duration
Disease state Duration (weeks) Number of trials Average discontinuation percent (%)
DPNP 12 1 24.9
13 2 20.2
FM 12 2 39.4
27 1 38.2
28 1 46.5
GAD 9 1 24.2
10 3 36.4
MDD 4 1 4.3
8 3 32.8
9 5 38.5
10 1 37.3
12 1 30.5
Abbreviations: MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder.
Table 4 Logistic regression results on impact of early therapeutic response and adverse reactions
D/C patients vs patients that complete therapy phase
Disease state Characteristic Odds ratio Order of selection p value
FMa STR 1.193 3rd 0.0019
SAR 1.234 1st 0.0002
MDDb STR 1.202 2nd 0.0001
SAR 1.146 3rd 0.0005
DPNPc STR NA Not selected NA
SAR 1.582 1st 0.0001
GADd STR 1.224 4th 0.0001
SAR 1.248 2nd 0.0001
Notes: Standardized therapeutic response is deﬁ  ned as the standardized scores of percent change in therapeutic response from baseline as measured by the primary efﬁ  cacy 
outcome measure in each disease state. Standardized Adverse Reaction is deﬁ  ned as standardized scores of maximum event severity deﬁ  ned as highest event severity in ﬁ  rst 
post-baseline visit for each patient. STR was not selected as a signiﬁ  cant predictor in logistic regression model for DPNP studies,
aFM studies also have country, duration, and age as signiﬁ  cant predictors. bMDD studies also have study, race, and age as signiﬁ  cant predictors. cDPNP studies also have country 
as a signiﬁ  cant predictor. dGAD studies also have study and age as a signiﬁ  cant predictor.
Abbreviations: D/C, discontinue; MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder; STR, 
Standardized Therapeutic Response; SAR, Standardized Adverse Reaction.Patient Preference and Adherence 2009:3 36
Nantz et al
disease state, the opposite was the case. The likelihood ratio 
test procedure demonstrated that that the inclusion of SAR 
contributed more to the ﬁ  nal Cox regression model than the 
inclusion of STR.
Completers versus patients
who discontinued
Within each disease state, therapeutic response values at 
each assessment were compared between the patients who 
completed the therapy phase and those who discontinued 
from the therapy phase as shown in Figures 1 to 4. For all 
disease states except MDD, there was no signiﬁ  cant differ-
ence in baseline values of primary outcome measure between 
the patients who completed and those who discontinued from 
the study. However, at each assessment after the baseline 
visit for the disease states MDD, GAD, and FM, patients 
who completed the study had signiﬁ  cantly greater thera-
peutic response than those who discontinued before the end 
of the therapy phase. Patients who completed the therapy 
phase in DPNP studies had signiﬁ  cantly greater therapeutic 
Table 5 Logistic regression likelihood ratio tests results
Disease state Model −2* log (L) Test statistic (reduced – full) p value
FM Full model 1803.256
Model excluding STR 1870.402 67.146 0.0001
Model excluding SAR 1816.878 13.622 0.0002
MDD Full model 3813.956
Model excluding STR 4017.629 203.673 0.0001
Model excluding SAR 3826.277 12.321 0.0005
DPNP Full model 1039.346
Model excluding STR 1129.263 89.917 0.0001
Model excluding SAR 1075.930 36.584 0.0001
GAD Full model 2204.893
Model excluding STR 2348.009 143.116 0.0001
Model excluding SAR 2222.770 17.877 0.0001
Notes: Chi-square statistic with 1 degree of freedom. Standardized Therapeutic Response is deﬁ  ned as the standardized scores of percent change in therapeutic response 
from baseline as measured by the primary efﬁ  cacy outcome measure in each disease state. Standardized Adverse Reaction is deﬁ  ned as standardized scores of maximum event 
severity deﬁ  ned as highest event severity in ﬁ  rst post-baseline visit for each patient.
Abbreviations: MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder; STR, Standardized Therapeutic 
Response; SAR, Standardized Adverse Reaction.
Table 6 Cox regression results on continuous effect of treatment response and adverse reactions
D/C patients vs patients that complete therapy phase
Disease state Characteristic Hazard ratio Order of selection P-value
FMa STR 1.446 1st 0.0001
SAR 1.446 2nd 0.0001
MDDb STR 1.443 1st 0.0001
SAR 1.337 2nd 0.0001
DPNPc STR 1.249 3rd 0.0005
SAR 1.869 1st 0.0001
GADd STR 1.452 1st 0.0001
SAR 1.472 2nd 0.0001
Notes: Standardized Therapeutic Response is deﬁ  ned as the standardized scores of percent change in therapeutic response from baseline as measured by the primary efﬁ  cacy 
outcome measure in each disease state. Standardized Adverse Reaction is deﬁ  ned as standardized scores of maximum event severity deﬁ  ned as highest event severity in ﬁ  rst 
post-baseline visit for each patients.
aFM studies also have country and duration as signiﬁ  cant predictors. bMDD studies also have study as a signiﬁ  cant predictor. cDPNP studies also have country as a signiﬁ  cant 
predictor. dGAD studies also have race, country, and age as signiﬁ  cant predictors.
Abbreviations: D/C, discontinue; MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder; STR, 
standardized therapeutic response; SAR, standardized adverse reaction.Patient Preference and Adherence 2009:3 37
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response in weeks 2 through 6 than patients who discontinued 
treatment.
Treatment response values at each assessment were also 
compared between the patients who completed the therapy 
phase and those who discontinued treatment due to lack of 
efﬁ  cacy, adverse events, and “other” reasons as shown in 
Figures 5 to 8. For all disease states except MDD, there was 
no signiﬁ  cant between-group difference in baseline values 
of the primary efﬁ  cacy outcome measure. Similar to the 
comparisons of therapy phase completers and those who 
discontinued from treatment, patients treated for MDD, 
GAD, and FM had signiﬁ  cant between-group differences 
Table 7 Cox regression likelihood ratio tests results
Disease state Model −2* log (L) Test statistic (reduced – full) p value
FM Full model 7197.040
Model excluding STR 7685.098 488.058 0.0001
Model excluding SAR 7263.800 66.760 0.0001
MDD Full model 12562.573
Model excluding STR 17330.680 4768.110 0.0001
Model excluding SAR 12630.626 68.053 0.0001
DPNP Full model 2940.973
Model excluding STR 2952.831 11.858 0.0006
Model excluding SAR 3037.452 96.479 0.0001
GAD Full model 7387.324
Model excluding STR 8764.248 1376.920 0.0001
Model excluding SAR 7458.218 70.894 0.0001
Notes: Chi-square statistic with 1 degree of freedom. standardized therapeutic response is deﬁ  ned as the standardized scores of percent change in therapeutic response 
from baseline as measured by the primary efﬁ  cacy outcome measure in each disease state. Standardized Adverse Reaction is deﬁ  ned as standardized scores of maximum event 
severity deﬁ  ned as highest event severity in ﬁ  rst post-baseline visit for each patient. 
Abbreviations: MDD, major depressive disorder; DPNP, diabetic peripheral neuropathic pain; FM, ﬁ  bromyalgia; GAD, generalized anxiety disorder; STR, Standardized Therapeutic 
Response; SAR, Standardized Adverse Reaction.
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Figure 1 Visit-wise 24-hour average pain severity scores between patients who completed therapy phase and those who discontinued early in DPNP studies.
Values are means across all treatments and studies.
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Figure 2  Visit-wise brief pain inventory scores between patients who completed therapy phase and those who discontinued early in ﬁ  bromyalgia studies.
Values are means across all treatments and studies.
*p value  0.05 between group differences. COM, completers; D/C, discontinue.
(N) denotes number of patients at speciﬁ  c time point.
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Figure 3 Visit-wise HAMA Total scores between patients who completed therapy phase and those who discontinued early in GAD studies.
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Figure 5 Visit-wise 24-hour average pain severity scores between patients who completed therapy phase and those who discontinued early for various reasons in DPNP 
studies.
Values are means across all treatments and studies.
*p value  0.05 between group differences. Avg, average; AE, adverse events; COM, completers; DC, discontinue; LOE, lack of efﬁ  cacy; OTH, other reasons.
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Figure 6 Visit-wise brief pain inventory scores between patients who completed therapy phase and those who discontinued early for various reasons in ﬁ  bromyalgia 
studies.
Values are means across all treatments and studies.
*p-value  0.05 between group differences. AE, adverse events; COM, completers; DC, discontinue; LOE: lack of efﬁ  cacy; OTH, other reasons.
(N) denotes number of patients at speciﬁ  c time point.
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Figure 8 Visit-wise HAMD-17 total scores between patients who completed therapy phase and those who discontinued early for various reasons in MDD studies.
Values are means across all treatments and studies.
*p value  0.05 between group differences. AE, adverse events; COM, completers; DC, discontinue; LOE, lack of efﬁ  cacy; OTH, other reasons.
(N) denotes number of patients at speciﬁ  c time point.
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at each week past the baseline visit. Patients treated for the 
DPNP disease state had signiﬁ  cant between-group differ-
ences in weeks 1 through 5. While patients who discontinued 
due to lack of efﬁ  cacy had the lowest therapeutic response, 
patients who discontinued due to adverse events showed 
similar therapeutic response as therapy completers in the ﬁ  rst 
5 weeks of treatment in all four disease states.
Discussion
The aim of our analyses was to investigate therapeutic 
response and adverse reactions as predictors of treatment 
discontinuation in multiple disease states. Early therapeu-
tic response as measured by standardized percent change 
in the primary efﬁ  cacy outcome measure and severity of 
adverse event as measured by standardized scale at ﬁ  rst post-
baseline visit were both signiﬁ  cant predictors of premature 
treatment discontinuation in MDD, GAD, and FM disease 
states. In diabetic neuropathy, early therapeutic response 
was not a statistically signiﬁ  cant predictor using the stepwise 
logistic regression procedure, but it signiﬁ  cantly improved 
the overall adequacy of the model according to the likelihood 
ratio test procedure. Continuous therapeutic response at each 
visit throughout the studies provided a greater contribution 
to the prediction models than adverse reactions in the MDD, 
GAD, and FM disease states, while the opposite was true for 
diabetic neuropathy trials. These ﬁ  ndings do not depend on 
the treatment group as the same results were seen within the 
placebo treated patients as well as within the duloxetine treated 
patients. Also study duration was not a signiﬁ  cant predictor of 
treatment discontinuation in three of the four disease states (see 
Table 3 for average discontinuation rates by duration in each 
disease state). These ﬁ  ndings highlight the need for increased 
awareness of patients’ response to treatment and adverse 
reactions in all stages of treatment. If a patient demonstrates 
inadequate treatment response or experiences severe adverse 
reactions to treatment, clinicians could alter treatment options, 
provide educational information, or utilize other interventions 
to help the patient achieve improved treatment response.
This research demonstrates that, contrary to the common 
belief that the onset of adverse events is the primary cause of 
discontinuation, therapeutic response plays just as important 
a role in predicting discontinuation. Results presented here Patient Preference and Adherence 2009:3 42
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indicate that early therapeutic response contributed more 
to the adequacy of the model predicting discontinuation 
than early adverse reactions in all four disease states. The 
fact that this occurred in all four disease states is consistent 
with ﬁ  ndings that discontinuation proﬁ  les are similar among 
antidepressants of the same class in MDD, GAD, and social 
anxiety disorder (SAD).22 Therapeutic response measured 
at each visit contributed more to the adequacy of the model 
predicting the risk of discontinuation than adverse reaction 
severity measured at each visit in all disease states except 
DPNP. For patients in DPNP clinical trials, adverse event 
severity measured at each visit was the primary predictor of 
the risk of discontinuation, indicating that these medically 
vulnerable patients could be either less tolerant or experienc-
ing more severe adverse events. Patients with diabetes may 
have been exposed to life-long therapies due to chronicity 
of their disease state and may have been less sensitive to 
therapeutic response within a relatively short period of time 
and more sensitive to adverse events.
Patients who discontinued prematurely from the 
treatment showed signiﬁ  cantly less improvement at most 
time points past the baseline visit. In three of the four dis-
ease states (DPNP, FM, MDD), patients who discontinued 
due to adverse events demonstrated symptom improvement 
comparable to patients completing the studies. This is not 
too surprising as similar results were found in analyses of 
schizophrenia clinical trials as well.19 While adverse events 
have been accepted as unavoidable consequences of effective 
treatment, these ﬁ  ndings provide quantitative evidence that 
adverse events could be signiﬁ  cant barriers to effective treat-
ment. It is thus critical for clinicians to provide guidance and 
education to patients about the importance of adherence to 
medication regimens especially when the adverse events are 
not excessively burdensome or the adverse events may be 
transient. GAD trials did not demonstrate a similar pattern 
of improvement in patients who discontinued due to adverse 
events, indicating the possibility that lack of efﬁ  cacy could 
have been a contributing factor to their discontinuation 
from treatment, even though adverse events were the cited 
reason for it.
Previous research has identiﬁ  ed a diverse set of predictors 
of attrition, such as sociodemographic factors, physical and 
mental factors, and study characteristics.23,24 Our research 
has also identiﬁ  ed a set of demographic factors predicting 
patient discontinuation across the four disease states, such as 
race and age in MDD and GAD studies and country in DPNP 
studies. Age has been found to be negatively associated with 
discontinuation in previous research among patients with 
depression, posttraumatic stress disorder, or social anxi-
ety disorder taking selective serotonin reuptake inhibitors 
(SSRIs).20 While the primary predictors of treatment efﬁ  cacy 
and adverse event severity were mostly consistent among the 
disease states, the patient populations are different enough to 
warrant separate analyses for each disease state.
One limitation of the present analysis is the lack of active 
treatment arms besides duloxetine in the majority of clinical 
trials used in this analysis. Only placebo-controlled trials 
with no other active treatment arms besides duloxetine were 
included in the DPNP and FM disease states, and only two 
studies in the GAD disease state included another active treat-
ment arm. The importance of therapeutic response and adverse 
reaction as predictors of discontinuation was consistent when 
interaction with treatment assignment was implemented in the 
prediction models. Further studies are needed to conﬁ  rm that 
the greater impact of therapeutic response over adverse reac-
tion is consistent across placebo and active treatment arms. 
Also, the reason of discontinuation recorded for patients may 
not capture the primary reason for discontinuation for some 
patients, although this is typically not the norm in clinical 
trials. For example, an investigator may have recorded 
the reason for discontinuation as “subject decision,” but the 
patient’s decision to discontinue could have been driven by 
a perceived lack of treatment efﬁ  cacy or medication intoler-
ability. One possible solution is to collect additional data such 
as the likelihood of a patient attending the next treatment 
session.7 In the FM and MDD trials, the majority of patients 
were treated within North America (89% and 85% respec-
tively), which may not be optimal in determining differences 
in discontinuation proﬁ  les between patients treated in North 
America and outside of it. Lastly, all but one of the clinical 
studies satisfying our selection criteria were phase III clinical 
studies, which could limit the generalizability of our results 
to patients in real-world settings.
In conclusion, the ﬁ  ndings of our research highlight the 
need for increased awareness and monitoring of patients’ 
medication intolerability and lack of therapeutic response in 
all phases of treatment, especially early on. While discon-
tinuation rates due to adverse events and lack of therapeutic 
response were different for each of the four disease states, 
early therapeutic response and adverse event severity as well 
as visit-wise therapeutic response and adverse event severity 
both signiﬁ  cantly predicted the risk of discontinuation in 
each disease state. This indicates that a high level vigilance 
is of great importance in every clinical practice relying on 
continuous pharmacotherapy. In therapeutic areas such as 
mood and pain studied in this research where patients can Patient Preference and Adherence 2009:3 43
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subjectively perceive therapeutic response, it is more likely 
that patients will evaluate the effectiveness of the therapy 
by weighing the cost against the beneﬁ  t and subsequently 
make their choices on adherence to the medication regimen. 
Guidance or interventions from clinicians could help patients 
to become more encouraged and engaged in their treatment 
with the goal of a maximized patient outcome.
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